Login
$BOLT
$5.80 -$0.28 (4.61%) Live

$BOLT SEC Filings

Filed On Filing
13 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary development focus

12 Nov 2026 SCHEDULE 13G/A
10 Nov 2026 Form 4: Coastlands Capital Lp, 10% owner

Bought 50,000 shares ($319K)

06 Nov 2026 Form 3: Coastlands Capital Lp, 10% owner

Holds 412,416 shares of Common Stock

06 Nov 2026 SCHEDULE 13G
27 Oct 2026 Form 4: Gujrathi Sheila, Director

Received 85,821 shares as a grant or award · Acquired 3,259.707 Series D Preferred Stock (Other Transaction)

27 Oct 2026 Form 3: Gujrathi Sheila, Director

No securities owned

23 Oct 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +6 more

PRINCE MERGER SUB II, LLC, a Delaware limited liability company;

06 Oct 2026 8-K: Entry into a Material Definitive Agreement

On October 1, 2026, Bolt Biotherapeutics, Inc. (the “Company”) entered into the Second Amendment to Lease (the “Second Lease Amendment”) with HCP LS Redwood City LLC, as landlord (the “Landlord”). The Second Lease Amendment amends that c...

21 Sep 2026 Form 4: Yonehiro Grant, Chief Operating Officer

Sold 1,417 shares ($5.35K) · Sold 4,909 shares ($16.3K) · Sold 6,850 shares ($22.2K)

21 Sep 2026 Form 4: Nemec Sarah, Senior VP, Finance and PAO

Bought 509 shares ($1.97K) · Sold 843 shares ($3.18K) · Sold 2,922 shares ($9.7K) · 1 more

21 Sep 2026 Form 4: Quinn William P., Director

Bought 637 shares ($2.47K) · Sold 1,889 shares ($7.13K) · Sold 6,545 shares ($21.7K) · 1 more

13 Aug 2026 SCHEDULE 13G
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results

11 Jun 2026 Form 4: Berner Laura, Director

Granted 5,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Laporte Kathleen, Director

Granted 5,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: Dupont Jakob, Director

Granted 5,000 Stock Option (Right to Buy)

11 Jun 2026 Form 4: O'callaghan Brian, Director

Granted 5,000 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support